Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study

Table 4 Changes in adjusted laboratory test values during exposure period from baseline in patients with diabetes mellitus or hyperlipidemia

Category	Laboratory tests	Olmesartan			Candesartan
		Mean	95% CI		Mean	95% CI		p value
			Lower	Upper		Lower	Upper
Diabetes mellitus	Lipid metabolism
	Δ Triglyceride (mmol/L)	-0.096	-0.194	0.003	0.108	-0.022	0.237	0.0228*
	Δ LDL-cholesterol (mmol/L)	-0.117	-0.183	-0.051	-0.101	-0.160	-0.041	0.7241
	Δ Total cholesterol (mmol/L)	-0.163	-0.246	-0.080	-0.089	-0.172	-0.005	0.2313
	Renal function
	Δ Urea nitrogen (mmol/L)	0.220	0.018	0.422	0.251	0.019	0.483	0.8514
	Δ Creatinine (μmol/L)	2.298	1.132	3.456	3.209	1.618	4.791	0.4025
	Δ Potassium (mmol/L)	0.047	-0.001	0.096	0.060	0.017	0.104	0.7
Hyperlipidemia	Lipid metabolism
	Δ Triglyceride (mmol/L)	-0.079	-0.203	0.044	0.106	-0.019	0.231	0.0498*
	Δ LDL-cholesterol (mmol/L)	-0.108	-0.177	-0.038	-0.087	-0.139	-0.036	0.6414
	Δ Total cholesterol (mmol/L)	-0.111	-0.196	-0.026	-0.060	-0.135	0.014	0.3877
	Renal function
	Δ Urea nitrogen (mmol/L)	0.401	0.174	0.629	0.231	0.034	0.428	0.2755
	Δ Creatinine (μmol/L)	2.157	0.857	3.448	2.661	1.308	4.005	0.6173
	Δ Potassium (mmol/L)	0.029	-0.015	0.073	0.049	0.012	0.086	0.5099

Δ indicates the mean change in laboratory test value during the exposure period from baseline. CI denotes confidence interval. *: p < 0.05 (candesartan vs olmesartan)

ISSN: 1475-2840